Journal Article

Real-world effectiveness of a single dose of mpox vaccine in males

Arieh, Noa Gur, Netzer, Doron, Yaron, Shlomit, Abu Ahmad, Wiessam, Peretz, Alon, Duskin-Bitan, Hadar, Wolff Sagy, Yael, Hammerman, Ariel, Lavie, Gil, Carmeli, Guy, Battat, Erez, Mark-Amir, Avner, Ramot, Noga, Wagner-Kolasko, Gal, Markovits, Hila, Zucker, Roy, Arbel, Ronen

2023

Overview

The recent global outbreak of the monkeypox (mpox) virus in humans was declared a public health emergency by the World Health Organization in July 2022. The smallpox and mpox vaccine (JYNNEOS; Modified Vaccinia Ankara-Bavarian Nordic; MVA-BN), provided as a two-dose regimen, is currently the primary vaccine utilized against mpox. However, the efficacy of MVA-BN against mpox has never been demonstrated in clinical trials to date. Due to the limited supply of vaccines, the World Health Organization has recommended prioritizing the vaccination of high-risk groups. We evaluated the real-world effectiveness of a single, subcutaneous dose of MVA-BN in this observational, retrospective cohort study, which included the analysis of electronic health records of all members of Clalit Health Services eligible for the vaccine on 31 July 2022. We used a Cox proportional hazards regression model with time-dependent covariates to estimate the association between vaccination and mpox while adjusting for sociodemographic and clinical risk factors. In an analysis of 2,054 male individuals who met vaccine eligibility criteria, 1,037 (50%) were vaccinated during the study recruitment period and completed at least 90 d of follow-up. During the study period, 5 and 16 infections were confirmed in vaccinated and unvaccinated individuals, respectively. The adjusted vaccine effectiveness was estimated at 86% (95% confidence interval, 59–95%). Our results suggest that a single dose of subcutaneous MVA-BN in this high-risk cohort is associated with a significantly lower risk of MPXV infection. Effectiveness of one subcutaneous dose of MVA-BN, the smallpox and mpox vaccine, was estimated to be 86% in a cohort of vaccine-eligible males in Israel, supporting its use to curtail the outbreak of mpox virus.

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 692/308/174 / 692/699/255 / Biomedical and Life Sciences / Biomedicine / Cancer Research / Clinical trials / Effectiveness / Electronic health records / Electronic medical records / Health services / Humans / Immunization / Infectious Diseases / Male / Males / Metabolic Diseases / Molecular Medicine / Mpox / Mpox (monkeypox) - prevention & control / Neurosciences / Outbreaks / Public health / Regression models / Retrospective Studies / Risk factors / Risk groups / Smallpox / Smallpox Vaccine - adverse effects / Statistical analysis / Vaccine efficacy / Vaccines / Vaccinia / Vaccinia virus / Viruses